NCT00428142 2026-03-27
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
18 trialsNCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT01190787 2024-01-23
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
European Myeloma Network B.V.
Phase 2 Completed
NCT01913730 2023-12-13
Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
Phase 2 Completed
NCT00030875 2023-08-04
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00377052 2023-08-04
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01045681 2020-12-07
BVD
Intergroupe Francophone du Myelome
Phase 2 Completed
NCT00598169 2020-08-10
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 1 Completed
NCT02219178 2020-07-17
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Cancer Trials Ireland
Phase 2 Completed
NCT00458913 2018-07-12
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03402295 2018-01-18
GBRAM003r
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Completed
NCT00376961 2017-11-06
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01460420 2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2 Completed
NCT00832234 2015-02-18
BDR-WM
European Myeloma Network B.V.
Phase 2 Completed
NCT00513877 2014-12-31
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Cancer Trials Ireland
Phase 2 Completed
NCT00814541 2014-12-31
PAD. ICORG 05-01, V11
Cancer Trials Ireland
Phase 2 Completed
NCT00098982 2013-06-12
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed